Daily Endocrinology Research Analysis
Analyzed 106 papers and selected 3 impactful papers.
Summary
Top endocrine research today spans translational biomaterials, immunoendocrinology, and real-world diabetes care. A self-regulating hydrogel accelerated healing in diabetic wounds from animal models to a pilot clinical study, while gender-affirming hormone therapy produced opposite cytokine shifts in transgender cohorts. Population-based CGM data in very old adults with type 2 diabetes revealed substantial nocturnal hypoglycemia, especially with insulin or sulfonylureas.
Research Themes
- Smart biomaterials for diabetic wound healing
- Sex-steroid modulation of immune networks in GAHT
- Population CGM to quantify hypoglycemia risk in older adults
Selected Articles
1. Self-regulating hydrogel for diabetic wound healing: From animal models to a pilot clinical study.
A smart, pH-responsive hydrogel (GPP@ZnBG) delivered antibacterial zinc early and pro-regenerative ions later, improving vascularization and wound closure in diabetic mice. In a pilot clinical study, topical application achieved a 94.57% relative wound area reduction at 4 weeks without adverse events, suggesting translational potential.
Impact: Introduces a mechanistically rational, self-regulated ion delivery platform validated from bench to bedside with early clinical signal in a major unmet need (diabetic wounds).
Clinical Implications: Offers a potentially safe, topical adjunct that targets both infection and regeneration. Could reduce amputations if efficacy is confirmed in controlled trials; suggests stage-tailored wound microenvironment modulation as a therapeutic strategy.
Key Findings
- GPP@ZnBG hydrogel released zinc under alkaline conditions early, conferring antibacterial effects while limiting toxicity.
- Later-stage degradation released zinc, calcium, and silicate ions that enhanced angiogenesis, dampened inflammation, and promoted tissue repair.
- In diabetic mice, hydrogel treatment improved neovascularization, collagen deposition, and wound closure.
- Single-cell RNA-seq showed hydrogel fine-tuned fibroblast NF-κB signaling to reduce maladaptive inflammation.
- Pilot clinical application achieved a 94.57% relative wound area reduction within 4 weeks without adverse events.
Methodological Strengths
- Translational pipeline from mechanistic design to in vivo validation and pilot clinical testing
- Single-cell RNA sequencing to delineate cellular and pathway-level effects
Limitations
- Pilot clinical study lacks a control arm and has short follow-up (4 weeks)
- Generalizability and long-term safety/effectiveness remain unproven; manufacturing and scalability need evaluation
Future Directions: Conduct randomized controlled trials comparing to standard care, assess durability and amputation outcomes, and optimize dose/schedule and patient selection based on wound stage and microenvironmental profiling.
Chronic diabetic wounds affect millions and often fail to heal due to infection, inflammation, and poor angiogenesis, leading to high rates of amputation. Current treatments offer limited control over the wound microenvironment. Here, this work develops GPP@ZnBG hydrogels that can respond to elevated glucose and oxidative stress in diabetic wounds to release therapeutic ions in a self-pH-regulated and sequential manner. At an early stage, this hydrogel initiates a release of zinc ions under alkaline conditions, providing antibacterial activity while avoiding toxicity from excessive dosing. During the late stage, the hydrogel degrades, and it steadily releases zinc, calcium, and silicate ions that support angiogenesis, reduce inflammation, and promote tissue repair. In diabetic mice, GPP@ZnBG hydrogels improve neovascularization and enhance collagen deposition, leading to enhanced wound closure. Single-cell RNA sequencing results indicate that the hydrogel modulates fibroblast behavior, specifically fine-tuning NF-κB signaling to reduce detrimental inflammation and promote wound repair. A pilot clinical study demonstrates that topical GPP@ZnBG application showed a 94.57% relative reduction in a wound surface area within 4 weeks, with no adverse events reported. These findings establish a self-pH-driven ion delivery strategy that targets both infection and tissue regeneration, offering a promising therapeutic platform for chronic diabetic wound care.
2. Cytokine Dynamics Following Initiation of Gender-Affirming Hormone Therapy in Transgender Subjects.
Over approximately six months of GAHT, trans women exhibited significant decreases in multiple cytokines/chemokines, while trans men showed increases in several immune factors. These opposite immunologic shifts imply sex steroid-dependent modulation that may contribute to sex differences in inflammatory disease risk.
Impact: Provides prospective, controlled biomarker evidence that sex steroids rapidly and differentially remodel human cytokine networks, informing mechanisms underlying sex gaps in autoimmunity and infection.
Clinical Implications: Supports vigilance for inflammatory and autoimmune phenotypes during GAHT and motivates tailored monitoring strategies; mechanistic insights may guide future risk stratification and adjunctive therapies.
Key Findings
- After ~6 months of estrogen plus antiandrogen therapy, trans women had significant decreases in 10 cytokines/chemokines (e.g., CCL2, CXCL9-11, IL-15) and an increase in IL-7.
- Testosterone therapy in trans men significantly increased eight immune factors (e.g., CCL2, CCL7, CCL11, CCL19, IL-17C, MMP1, TNFSF10).
- hs-CRP showed no clinically meaningful change, suggesting specific cytokine network remodeling rather than broad inflammatory shifts.
- Findings suggest sex steroid-dependent and directionally opposite immune modulation between feminizing and masculinizing GAHT.
Methodological Strengths
- Prospective before–after design with cisgender controls
- Multiplex proteomic profiling (Olink) and LC-MS/MS sex steroid quantification
Limitations
- Moderate sample size and ~6-month follow-up limit detection of clinical outcomes
- Causality and pathway attribution require mechanistic studies
Future Directions: Link cytokine changes to clinical phenotypes (autoimmunity, infection), dissect cell-specific mechanisms, and test whether regimen/dose adjustments modulate immune risk.
BACKGROUND: Sex is an important determinant for various immune system-related pathologies and sex steroids might possess immunomodulatory properties. OBJECTIVE: To study the effects of sex steroid exposure on the serum levels of immune-related biomarkers (irBMS), using a model of transgender individuals receiving gender-affirming hormone therapy (GAHT). MATERIAL AND METHODS: Serum samples were collected from hormone-naïve trans women (TW) (n=30) and trans men (TM) (n=30) who initiated GAHT at baseline and after ±6 months of treatment. Cisgender men (n=10) and cisgender women (n=10) were included as controls. High-sensitivity C-reactive protein (hs-CRP) was measured using immunoassay. Serum levels of several irBMs, including cytokines and chemokines were determined using a commercial multiplex assay (Olink®). Serum estradiol and testosterone were determined using liquid-chromatography tandem mass spectrometry (LC-MS/MS). RESULTS: After ±6 months of GAHT in TW, serum levels of ten cytokines (CCL2, CCL7, CCL11, CCL13, CCL19, CXCL9, CXCL10, CXCL11, IL15 and TNFSF10) significantly decreased, whereas IL7 increased. In TM, eight factors significantly increased (CCL2, CCL7, CCL11, CCL13, CCL19, IL17C, MMP1 and TNFSF10). Other immune-related biomarkers were not significantly affected, and levels of hs-CRP did not show a clinically relevant change over time. CONCLUSION: Six months of estrogen with antiandrogen treatment resulted in decreased serum levels of several cytokines and chemokines in TW, whereas cytokine and chemokine levels often increased in TM upon treatment with testosterone. These distinct and generally opposite changes suggest a sex steroid-dependent impact, which could contribute to sex-related disparities in (auto)inflammatory diseases. However, additional research should explore potential clinical consequences, as well as the mechanisms involved.
3. Burden and Risk Factors of CGM-Detected Hypoglycemia in Older Adults With Type 2 Diabetes.
In a population-based cohort of very old adults with type 2 diabetes, CGM revealed frequent and prolonged nocturnal hypoglycemia among those on insulin or sulfonylureas, with two-thirds exceeding recommended hypoglycemia thresholds. Comorbidities (CVD, cognitive impairment, CKD, poor function) were associated with greater hypoglycemia burden.
Impact: Quantifies real-world hypoglycemia burden in very old adults using CGM at scale, directly informing de-intensification and safer prescribing in geriatric diabetes care.
Clinical Implications: Supports routine CGM use or intermittent CGM audits in very old adults on insulin/sulfonylureas, prioritizing nocturnal monitoring, comorbidity-informed de-intensification, and individualized glycemic targets.
Key Findings
- Among insulin/sulfonylurea users, median time <70 mg/dL was 3.4%, and ~66% exceeded the <1% hypoglycemia target.
- Hypoglycemic episodes were typically nocturnal and lasted a median ~1.5 hours in high-risk medication users.
- In non-users of insulin/sulfonylureas, hypoglycemia burden was low (median 0.7% time <70 mg/dL).
- Cardiovascular disease, cognitive impairment, poor physical function, and CKD were associated with more hypoglycemia regardless of medication strata.
Methodological Strengths
- Population-based sampling of very old adults with standardized CGM metrics
- Stratification by high-risk medications to contextualize risk
Limitations
- Cross-sectional design precludes causal inference and outcome linkage
- Potential residual confounding and limited detail on CGM wear duration/algorithms in abstract
Future Directions: Prospective studies to test CGM-guided de-intensification protocols, evaluate cognitive/falls outcomes, and refine nocturnal hypoglycemia prevention in geriatric care.
BACKGROUND: Comprehensive data on the burden of biochemical hypoglycemia in older adults with type 2 diabetes are lacking. We seek to characterize the burden and risk factors for hypoglycemia detected by continuous glucose monitoring (CGM) in older adults with type 2 diabetes. METHODS: A cross-sectional analysis of 315 older adults with type 2 diabetes who attended visit 9 of the Atherosclerosis Risk in Communities Study (2021-2022). We examined rates of Level 1 hypoglycemia (< 70 mg/dL) and percentage meeting recommended targets for hypoglycemia (< 1% of time). We identified risk factors for CGM-detected hypoglycemia by comparing the median time spent in hypoglycemia across subgroups. All analyses were stratified by high-risk medication use (insulin/sulfonylureas vs. not). RESULTS: Of the 315 participants with type 2 diabetes (mean age 83 years, 55% women, 41% Black adults), 32.4% were using insulin or sulfonylureas. Among individuals using these high-risk medications, the median time spent in hypoglycemia was 3.4%, and ~66% of participants spent more than 1% of the time with CGM glucose < 70 mg/dL. Hypoglycemic episodes typically occurred overnight and lasted a median of ~1.5 h among individuals using insulin or sulfonylureas. CGM-detected hypoglycemia was low in participants not using high-risk medications (median time spent in hypoglycemia: 0.7%). In unadjusted analyses, cardiovascular disease, cognitive impairment, poor physical functioning, and chronic kidney disease were associated with increased time spent in hypoglycemia, regardless of high-risk medication use. CONCLUSIONS: There may be a substantial burden of unrecognized CGM-detected hypoglycemia in very old adults with type 2 diabetes using high-risk medications in the general population. Hypoglycemia may also be present among persons not on high-risk medication, but the burden is much lower. Further research is needed to clarify the clinical significance of these hypoglycemic episodes.